INTRODUCTION
The term mixed adenoneuroendocrine carcinoma (MANEC) was introduced by the World Health Organization (WHO) in 2010, referring to a neoplasm with dual adenocarcinomatous and neuroendocrine differentiation, each component representing at least 30% of the tumor [1] . MANEC is a rare tumor that has been presented only as a case report, with only 40 cases reported to date in the English litera ture. Owing to its rarity, the treatment of MANEC is unclear. In this report, we present a rare case of a gastric MANEC treated with distal gastrectomy.
CASE REPORT
A 65-year-old man was admitted to the hospital under the diagnosis of neuroendocrine tumor. An ulcerative depressed lesion measuring 3 cm in diameter was found in the lower gastric body on a routine endoscopic checkup. Endoscopic biopsy revealed a neuroendocrine tumor, grade I, and immuno histo-Mixed adenoneuroendocrine carcinoma (MANEC) is a rare disease that was first defined in the 2010 World Health Organization classification of endocrine tumors. We present the case of a 65-year-old man with an ulcerative depressed lesion measuring 3 cm in diameter and found in the lower gastric body. It was diagnosed as a MANEC, and we performed subtotal gastrectomy with D2 lymph node dissection. The patient is still alive, and no recurrence was observed at a 12-month follow-up. Most MANECs tend to have a poor prognosis. Curative resection, including an adequate lymph node dissection, should be considered, and intense follow-up is needed. Gross specimen opened at greater curvature. It shows a well-defined ovoid submucosal mass (mass 1) with mucosal ulcera tion, measuring 2.5 cm × 1.7 cm in size lower body of anterior wall. And it shows a well-defined multinodular submucosal mass (mass 2) at lesser curvature of lower body, measuring 4.7 cm × 2.8 cm in size. The masses 1 and 2 show yellow white homogenous cut surface without necrosis. The mass 2 is involving mucosa and extend to subserosa, grossly.
chemistry was positive for panCK, synaptophysin, CD56, physin, and CD56. Laboratory data were normal, including the tumor markers CA 19-9 and CEA. Computed tomography revealed a highly enhanced mass 2.1 cm in diameter at the anterior wall of the gastric body, with multiple highly enhanced lymph node enlargements. The patient underwent total laparoscopic distal gastrectomy with Billroth II gastrojejunostomy with Braun anastomosis. No tumor was found in the frozen sections from the proximal and distal margins. The pathology report showed a well-defined ovoid submucosal mass (mass 1) with mucosal ulceration, measuring 2.5 cm × 1.7 cm in size, at the lower body of the anterior wall. It showed a well-defined multinodular submucosal mass (mass 2) at the lesser curvature of the lower body, measuring 4.7 cm × 2.8 cm in size. Masses 1 and 2 showed a yellow-white homogenous cut surface without necrosis. Mass 2 grossly involved the mucosa, extending to the subserosa (Figs. 1, 2) . A final diagnosis of MANEC with neuroendocrine car ci noma involving the muscularis propria (pT2) was made, without metastasis to 28 regional lymph nodes (pN0). Im mu no histochemistry was negative for CD56 but positive for synaptophysin, chromogranin, and p53 (Fig. 3) . The patient recovered well and was discharged on postoperative day 10. We recommended chemotherapy for the patient, but he did not want to be treated with adjuvant chemotherapy. Nevertheless, no recurrence was observed at the 12-month follow-up after the surgery.
Written informed consent was obtained from the patients before the publication of this case report and accompanying images. [8] 77/F pT4aN0 G3 6 Months Gurzu et al. [9] 46/M pT4bN3b G3 Death within 5 months Kwok et al. [10] 83/M pT3N1 G2 Death within 8 months the neuroendocrine features of gastric cancer. According to the results of the previous study, gastric carcinoma that contains neuroendocrine components is an intestinal type rather than a diffuse type. The mean patient age is 58 years, and the polypoid lesions are usually located in the lower third of the stomach [2] . Although some authors sustain that clinical behavior depends on the grade of the neuroendocrine component, others reveal that the characteristics of the adenocarcinoma component influence the outcome in well-differentiated neuroendocrine components [2, 3] . Even though good prognosis of MANEC was reported [4] , most cases are believed to be rapidly growing lesions, with most patients showing a poor prognosis [5, 6] . The assessment of MANEC is still incomplete because the results of the studies conducted before 2010 did not reflect the exact definition. Neuroendocrine carcinoma is known to frequently invade the lymphatic and vascular lumens and subsequently metastasize to the lymph nodes and liver, even during the early stages, owing to its aggressive biological behavior. The biological behavior of MANEC is similar to that of NEC.
DISCUSSION
In the literature review, recent reports seem to suggest that lymph node metastasis found during surgery is an important prognostic factor (Table 1) . Cases with lymph node metastasis tended to be malignant. In our patient, we found no lymph node metastasis coexisting with any other distal metastasis. We assumed that our patient underwent curative surgery before malignant features of the disease were observed. A substantial number of cases should be studied to prove this hypothesis. Nevertheless, intense follow-up for possible recurrence is necessary, as the disease can lead to poor prognosis.
The optimal treatment of MANEC is unclear because of the rarity of the tumor. However, MANECs containing a poorly differentiated NEC component should be treated as NECs [7] . Even though the MANEC in our patient contained a well-differentiated NEC component, we considered applying platinum-based chemotherapy because of the associated poor prognosis. However, our patient refused to receive any adjuvant chemotherapy after the operation. Nevertheless, the patient had no signs of recurrence after the operation.
Most MANECs tend to have a poor prognosis. Thus, curative resection should be considered, and adjuvant chemotherapy with intense follow-up is needed.
